Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances

被引：16
作者：
Mohamed, Amr [1 ]
Strosberg, Jonathan R. [1 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2019年 / 60卷 / 06期
关键词：
management; gastroenteropancreatic neuroendocrine tumors; carcinoid tumors; systemic treatment; RECEPTOR RADIONUCLIDE THERAPY; CARCINOID-SYNDROME; PHASE-II; HIGH-GRADE; TEMOZOLOMIDE; EVEROLIMUS; SURVIVAL; TRIAL; STREPTOZOCIN; CAPECITABINE;
D O I：
10.2967/jnumed.118.214882
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Gastroenteropancreatic neuroendocrine tumors are relatively rare neoplasms, characterized by a propensity to secrete hormones that cause distinct clinical syndromes. During the past decade, the systemic treatment landscape has improved significantly: new options include everolimus, an inhibitor of the mammalian target of rapamycin; sunitinib, an angiogenesis inhibitor; and cytotoxic regimens such as capecitabine and temozolomide. Moreover, the recent approval of the radiolabeled somatostatin analog Lu-177-DOTATATE has had a significant impact on management of neuroendocrine malignancies. In this review, we discuss advances in the medical management of gastroenteropancreatic neuroendocrine tumors within the context of the larger multidisciplinary approach to these diseases.
引用
收藏
页码：721 / 727
页数：7
相关论文
共 69 条
  • [1] Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
    Anthony, LB
    Woltering, EA
    Espenan, GD
    Cronin, MD
    Maloney, TJ
    McCarthy, KE
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) : 123 - 132
  • [2] Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives
    Baldelli, Roberto
    Barnabei, A.
    Rizza, L.
    Isidori, A. M.
    Rota, F.
    Di Giacinto, P.
    Paoloni, A.
    Torino, F.
    Corsello, S. M.
    Lenzi, A.
    Appetecchia, M.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2014, 5
  • [3] Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases
    Barbier, Charlotte Ebeling
    Garske-Roman, Ulrike
    Sandstrom, Mattias
    Nyman, Rickard
    Granberg, Dan
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (08) : 1425 - 1431
  • [4] The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
    Basturk, Olca
    Yang, Zhaohai
    Tang, Laura H.
    Hruban, Ralph H.
    Adsay, Volkan
    McCall, Chad M.
    Krasinskas, Alyssa M.
    Jang, Kee-Taek
    Frankel, Wendy L.
    Balci, Serdar
    Sigel, Carlie
    Klimstra, David S.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (05) : 683 - 690
  • [5] Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas A Clinicopathologic Analysis of 44 Cases
    Basturk, Olca
    Tang, Laura
    Hruban, Ralph H.
    Adsay, Volkan
    Yang, Zhaohai
    Krasinskas, Alyssa M.
    Vakiani, Efsevia
    La Rosa, Stefano
    Jang, Kee-Taek
    Frankel, Wendy L.
    Liu, Xiuli
    Zhang, Lizhi
    Giordano, Thomas J.
    Bellizzi, Andrew M.
    Chen, Jey-Hsin
    Shi, Chanjuan
    Allen, Peter
    Reidy, Diane L.
    Wolfgang, Christopher L.
    Saka, Burcu
    Rezaee, Neda
    Deshpande, Vikram
    Klimstra, David S.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (04) : 437 - 447
  • [6] PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
    Bodei, Lisa
    Kidd, Mark S.
    Singh, Aviral
    van der Zwan, Wouter A.
    Severi, Stefano
    Drozdov, Ignat A.
    Cwikla, Jaroslaw
    Baum, Richard P.
    Kwekkeboom, Dik J.
    Paganelli, Giovanni
    Krenning, Eric P.
    Modlin, Irvin M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (07) : 1155 - 1169
  • [7] Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
    Bodei, Lisa
    Kidd, Mark
    Paganelli, Giovanni
    Grana, Chiara M.
    Drozdov, Ignat
    Cremonesi, Marta
    Lepensky, Christopher
    Kwekkeboom, Dik J.
    Baum, Richard P.
    Krenning, Eric P.
    Modlin, Irvin M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (01) : 5 - 19
  • [8] First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
    Bongiovanni, Alberto
    Riva, Nada
    Ricci, Marianna
    Liverani, Chiara
    La Manna, Federico
    De Vita, Alessandro
    Foca, Flavia
    Mercatali, Laura
    Severi, Stefano
    Amadori, Dino
    Ibrahim, Toni
    [J]. ONCOTARGETS AND THERAPY, 2015, 8 : 3613 - 3619
  • [9] Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
    Brabander, Tessa
    van der Zwan, Wouter A.
    Teunissen, Jaap J. M.
    Kam, Boen L. R.
    Feelders, Richard A.
    de Herder, Wouter W.
    van Eijck, Casper H. J.
    Franssen, Gaston J. H.
    Krenning, Eric P.
    Kwekkeboom, Dik J.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4617 - 4624
  • [10] Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2-clinical implications
    Cakir, Mehtap
    Dworakowska, Dorota
    Grossman, Ashley
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (11) : 2585 - 2591
1234567